MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

Original reporting
Published Nov 17, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$MTVA
Bullish
medium confidence
Mentioned
$MTVA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

Completion of the Phase 1 final study visit and interim improvements in liver fat and metabolic measures can improve development confidence, but the next major catalyst is the full Parts 3A and 3B data release in 1Q 2027 and Phase 2 initiation in 2H 2027.

02

Market read

Traders may adjust biotech risk pricing based on Phase 1 completion and interim MRI-PDFF/weight/glycemic improvements, while awaiting final datasets.

03

What to watch

Key missing items include full adverse-event profile, durability beyond the 16-week regimen, and whether the extended Part 3A dosing changes tolerability or effect size.

Relevance 7/10Novelty 7/10Timing: today’s Phase 1 completion update, with full data expected in 1Q 2027

Background

MetaVia is evaluating DA-1726, a once-weekly GLP-1/glucagon dual-receptor agonist, in Phase 1 for liver-related cardiometabolic diseases.

Company-level read

Ticker impact

$MTVABullishMedium confidence
Context

MetaVia says the last patient completed Phase 1 final visit for DA-1726 and extended Part 3A to 24 weeks with updated dosing and interim MRI-PDFF results.

Expected impact

Likely near-term support as traders price improved probability of continued development, with upside capped until full Part 3A/3B data.

Evidence & confidence

The article provides concrete interim efficacy metrics and trial completion, but does not include final datasets, adverse-event details, or Phase 2 outcomes.

Market effects

Adds incremental signal for GLP-1/glucagon dual agonist development in liver-related cardiometabolic disease, relevant to metabolic and NASH-adjacent biotech sentiment.

No direct regional market linkage beyond US biotech risk appetite.

Modest global relevance as it is a single-company Phase 1 update, not a cross-market regulatory or approval event.

Counterpoint

Interim Phase 1 MRI-PDFF and weight metrics may not translate into durable clinical endpoints; without full safety and efficacy, the market may fade the news.

Key entities

  • MetaVia Inc.

    NASDAQ-listed biotech developing DA-1726 for liver-related cardiometabolic diseases.

  • DA-1726

    Once-weekly GLP-1/glucagon dual-receptor agonist evaluated in Phase 1 Parts 3A and 3B.

Related articles

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 ​ Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks ​ Positive Part 3B I

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) presented preclinical data at ObesityWeek 2026, showing its drug DA-1726 increased liver FGF21 expression and achieved weight loss comparable to retatrutide with less food intake suppression. The company plans to start a Phase 2 study for MetALD and ALD in late 2027. DA-1726 demonstrated greater glucose lowering and favorable lipid effects. According to MetaVia, the results support DA-1726's potential in liver-related cardiometabolic diseases.